Faro raises $37.3 M Series B to accelerate clinical trials, backed by Merck Global Health Innovation Fund and S32
agents
| Source: Techmeme | Original article
Faro, which builds data models and AI tools to accelerate clinical trials, raised a $37.3 million Series B round co‑led by Merck Global Health Innovation Fund and S32.
Faro, a specialist in data models and AI tools for clinical development, announced a $37.3 million Series B financing round co‑led by Merck Global Health Innovation Fund and venture firm S32. The capital will be used to expand the company’s “agentic AI” platform, which translates complex scientific, medical, regulatory and operational concepts into structured intent that software agents can reason over and act upon.
Faro’s technology underpins a suite of capabilities that help drug‑development teams design and operationalise studies, generate protocol and other clinical documents, flag risks and inconsistencies, and automate increasingly complex workflow steps. Its proprietary ontology and data infrastructure are already employed by six of the world’s ten largest pharmaceutical companies, positioning the firm as a critical back‑end for modernising trial processes.
The raise matters because accelerating clinical‑trial design and execution can shave months off drug‑development timelines and reduce the high costs that have traditionally hampered the industry. By automating routine but intricate tasks such as protocol drafting, Faro aims to free scientists to focus on hypothesis testing and patient outcomes, potentially bringing therapies to market faster.
Going forward, observers will watch how Faro allocates the new funding to broaden its AI‑driven services across the full development lifecycle and whether additional pharma partners adopt its platform. The rollout of its generative‑AI “Study Designer” for protocol writing, highlighted in recent product briefs, may serve as a bellwether for the broader impact of AI on clinical‑trial efficiency.
Sources
Back to AIPULSEN